Literature DB >> 24408920

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response.

Jaikumar Duraiswamy1, Gordon J Freeman, George Coukos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24408920     DOI： 10.1158/0008-5472.CAN-13-2752

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  21 in total

Review 1.  Biomarkers for glioma immunotherapy: the next generation.

Authors:  Jennifer S Sims; Timothy H Ung; Justin A Neira; Peter Canoll; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2015-02-28       Impact factor: 4.130

2.  Assessment of PD-1 positive cells on initial and secondary resected tumor specimens of newly diagnosed glioblastoma and its implications on patient outcome.

Authors:  Tsubasa Miyazaki; Eiichi Ishikawa; Masahide Matsuda; Hiroyoshi Akutsu; Satoru Osuka; Noriaki Sakamoto; Shingo Takano; Tetsuya Yamamoto; Koji Tsuboi; Akira Matsumura
Journal:  J Neurooncol       Date:  2017-04-26       Impact factor: 4.130

3.  Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation.

Authors:  Chuan-Kun Shan; Yi-Bo Du; Xiao-Tian Zhai; Yue-Xuan Wang; Yi Li; Jian-Hua Gong; Zhi-Juan Ge; Xiu-Jun Liu; Yong-Su Zhen
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

4.  TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.

Authors:  Heng-Jia Liu; Patrick H Lizotte; Heng Du; Maria C Speranza; Hilaire C Lam; Spencer Vaughan; Nicola Alesi; Kwok-Kin Wong; Gordon J Freeman; Arlene H Sharpe; Elizabeth P Henske
Journal:  JCI Insight       Date:  2018-04-19

5.  Immuno-Oncology: The Third Paradigm in Early Drug Development.

Authors:  Juan Martin-Liberal; Cinta Hierro; Maria Ochoa de Olza; Jordi Rodon
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.493

Review 6.  Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation.

Authors:  Lana E Kandalaft; Denarda Dangaj Laniti; George Coukos
Journal:  Nat Rev Cancer       Date:  2022-09-15       Impact factor: 69.800

7.  δ-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8+ T cell activation.

Authors:  Fei Huang; Junying Chen; Ruilong Lan; Zeng Wang; Ruiqing Chen; Jingan Lin; Lurong Zhang; Lengxi Fu
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

8.  Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.

Authors:  Weiqing Jing; Jill A Gershan; James Weber; Dominique Tlomak; Laura McOlash; Catherine Sabatos-Peyton; Bryon D Johnson
Journal:  J Immunother Cancer       Date:  2015-01-20       Impact factor: 13.751

9.  PD-1 blockade induces responses by inhibiting adaptive immune resistance.

Authors:  Paul C Tumeh; Christina L Harview; Jennifer H Yearley; I Peter Shintaku; Emma J M Taylor; Lidia Robert; Bartosz Chmielowski; Marko Spasic; Gina Henry; Voicu Ciobanu; Alisha N West; Manuel Carmona; Christine Kivork; Elizabeth Seja; Grace Cherry; Antonio J Gutierrez; Tristan R Grogan; Christine Mateus; Gorana Tomasic; John A Glaspy; Ryan O Emerson; Harlan Robins; Robert H Pierce; David A Elashoff; Caroline Robert; Antoni Ribas
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

Review 10.  An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Authors:  Martha R Neagu; David A Reardon
Journal:  Curr Treat Options Oncol       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.